QS-21 news

All news on QS-21 (also known as STIMULON QS-21 and Quillaja saponin QS-21): plants, production capacities, investments and involved companies.

18 May 2026

GSK’s Arexvy gains expanded approval in Japan for at‑risk adults 18–59

Approval now explicitly includes immunocompromised adults; Phase IIIb showed non‑inferior immune response versus older adults and a safety profile consistent with prior trials.

Who will be producing QS-21 in the future?

Find out with chemXplore Alpha

Learn more